A share price of Immunovant Inc [IMVT] is currently trading at $21.27, up 4.01%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMVT shares have gain 7.10% over the last week, with a monthly amount drifted -8.44%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on January 03, 2025, when Wolfe Research downgraded its rating to a Peer Perform. On October 09, 2024, Oppenheimer reiterated its Outperform rating and revised its price target to $53 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $50 on March 28, 2024. Goldman initiated its recommendation with a Buy and recommended $50 as its price target on March 13, 2024. JP Morgan started tracking with a Overweight rating for this stock on February 20, 2024, and assigned it a price target of $51. In a note dated February 15, 2024, Wolfe Research initiated an Outperform rating and provided a target price of $55 on this stock.
Immunovant Inc experienced fluctuations in its stock price throughout the past year between $19.07 and $39.55. Currently, Wall Street analysts expect the stock to reach $51 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $21.27 at the most recent close of the market. An investor can expect a potential return of 139.77% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -270.14%, Pretax Profit Margin comes in at -254.78%, and Net Profit Margin reading is -255.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.91, Equity is -0.78 and Total Capital is -1.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 20.83 points at the first support level, and at 20.38 for the second support level. However, for the 1st resistance point, the stock is sitting at 21.69, and for the 2nd resistance point, it is at 22.10.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Immunovant Inc [NASDAQ:IMVT] is 6.04. As well, the Quick Ratio is 6.04, while the Cash Ratio is 5.48.
Transactions by insiders
Recent insider trading involved Macias William L., Chief Medical Officer, that happened on Feb 19 ’25 when 2055.0 shares were sold. Chief Financial Officer, Barnett Eva Renee completed a deal on Feb 19 ’25 to sell 2814.0 shares. Meanwhile, Chief Executive Officer Salzmann Peter sold 15439.0 shares on Feb 19 ’25.
